Mercia invests £2 million in transdermal drug delivery specialist

Medherant, which is developing the TEPI Patch, received its first investment from Medilink West Midlands member Mercia’s managed funds in 2015.

Since then the company has developed an extensive patent estate and secured an exclusive worldwide licence from Bostik SA for the medical use of a novel adhesive. Mercia now holds a 33.6% direct equity stake in the business. This latest investment will enable Medherant to finalise the selection of three TEPI Patch products to take into clinical development. 

Nigel Davis, CEO of Medherant, said: “TEPI Patch technology holds great promise as a better way of delivering many different types of drugs. We are pleased to have supportive investors led by Mercia who are enabling us to progress the development of patch products that will bring significant benefits to patients across the globe.”